Navigation Links
Patent for Making Combination Chemotherapy Work Better
Date:3/24/2009

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the combination of the underlying drugs. Novel synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase depletion, greatly reducing the number of cancer cells killed by the S-Phase cytotoxic." The patent provides a crucial modification to the protocols by adding existing drugs to provide S-Phase enrichment at the appropriate time, while using the HER1 blocker to inhibit tumor regrowth between administrations of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, wh
'/>"/>

SOURCE NexGen Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
3. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. VIASPACE Granted US Patent
6. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
7. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
8. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
9. InterMune Announces Issuance of U.S. Patent for ITMN-191
10. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... York (PRWEB) July 25, 2014 According ... Research, "Biological Drugs Market - Global Industry Analysis, Size, ... global biological drugs market is estimated at USD 161,056.5 ... a CAGR of 10.1% from 2014 to 2020, to ... 2020. , The biological drugs market is witnessing a ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 At the request ... granted a 60-day extension for the public comment period ... Rule for Model Aircraft established by Congress as part ... The 60-day extension establishes the new deadline for comments ... Department of Transportation/FAA notice published in the Federal Register ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the Third Quarter 2007 financial results.,Michael S. ... will,host the call. Keryx will announce its financial results ... prior to the call. In order to participate ...
... Positive Phase I Results for R1507, COPENHAGEN, October ... from a Phase I study of R1507 in patients,with ... a human,monoclonal antibody targeting the insulin-like growth factor receptor,(IGF-1R) ... Nine of 34 adult patients with solid tumors experienced ...
... Calif., Oct. 23 InVitria has released ... factor for cell culture,media outperforms transferrin and ... Because Lacromin is produced in a completely,animal-free ... over,animal-derived alternatives including bovine and human transferrin. ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 3InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin 2
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... diffusion tensor tractography (DTT), which is derived from ... for three motor tracts, such as the corticospinal ... became possible. The corticospinal tract is known to ... in the human brain. Several studies have reported ... herniation. In addition, some studies have demonstrated recovery ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Bacteria manipulate salt to build shelters to hibernate 2
... 2, 2014 EcoHealth Alliance, a nonprofit organization ... issues, and Bat Conservation International, which works to ... are joining forces in formal partnership. The organizations ... and public health programs that enhance outreach with ...
... N.C. A new Duke University-led study has documented dramatic, ... estuary. "The natural short-term variability in acidity ... global predictions for the ocean as a whole and may ... organisms, particularly shelled organisms that are especially susceptible to changes ...
... centuries as a pain reliever in Chinese medicine may be ... chronic pain. A key pain-relieving ingredient is a compound known ... plant Corydalis , a member of the poppy family, ... Press journal Current Biology on January 2. ...
Cached Biology News:EcoHealth Alliance and Bat Conservation International forge partnership to work on global bat conservation and public health issues 2Local factors cause dramatic spikes in coastal ocean acidity 2Plant used in Chinese medicine fights chronic pain 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: